BMET-18 ASSESSING CENTRAL NERVOUS SYSTEM (CNS) RESPONSE TO ALECTINIB IN TWO PHASE II STUDIES OF PRE-TREATED ALK+ NON-SMALL CELL LUNG CANCER (NSCLC): RECIST VERSUS RANO CRITERIA

Παρόμοια τεκμήρια

• Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC
  ανά: Gadgeel, Shirish, κ.ά.
  Έκδοση: (2018)
• Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non–Small-Cell Lung Cancer
  ανά: Gadgeel, Shirish M., κ.ά.
  Έκδοση: (2016)
• Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer
  ανά: Shaw, Alice T., κ.ά.
  Έκδοση: (2015)
• Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases
  ανά: Lin, Jessica J., κ.ά.
  Έκδοση: (2018)
• Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer
  ανά: Ou, Sai-Hong Ignatius, κ.ά.
  Έκδοση: (2018)